Cargando…

A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats

BACKGROUND: Duvelisib (DUV) is a new oral phosphoinositide-3-kinase (PI3K)-δ and PI3K-γ inhibitor. It has been recently granted an accelerated approval for treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is also effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayed, Ahmed Y, Khalil, Nasr Y, Almomen, Aliyah, Alzoman, Nourah Z, Almehizia, Abdulrahman A, Darwish, Ibrahim A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232391/
https://www.ncbi.nlm.nih.gov/pubmed/34188446
http://dx.doi.org/10.2147/DDDT.S318714
_version_ 1783713626671022080
author Sayed, Ahmed Y
Khalil, Nasr Y
Almomen, Aliyah
Alzoman, Nourah Z
Almehizia, Abdulrahman A
Darwish, Ibrahim A
author_facet Sayed, Ahmed Y
Khalil, Nasr Y
Almomen, Aliyah
Alzoman, Nourah Z
Almehizia, Abdulrahman A
Darwish, Ibrahim A
author_sort Sayed, Ahmed Y
collection PubMed
description BACKGROUND: Duvelisib (DUV) is a new oral phosphoinositide-3-kinase (PI3K)-δ and PI3K-γ inhibitor. It has been recently granted an accelerated approval for treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is also effective in therapy of T-cell lymphoma, solid tumors, and non-Hodgkin’s lymphoma. In literature, there is no method valid for quantitation of DUV in human plasma for its therapeutic monitoring and pharmacokinetic studies. PURPOSE: The purpose of this study is the establishment of a highly sensitive HPLC method with fluorescence detection for quantitation of DUV in plasma for its therapeutic monitoring and pharmacokinetic studies of DUV. METHODS: The resolution of DUV and the internal standard (IS) olaparib (OLA) was achieved on Nucleosil CN column, with a mobile phase composed of acetonitrile:water (25:75, v/v) at a flow rate of 1.7 mL min(–1). The fluorescence of both DUV and OLA was detected at 410 nm after excitation at 280 nm. The method was validated according to the guidelines of bioanalytical method validation. RESULTS: The method was linear in the range of 5–100 ng mL(–1), and its limit of detection (LOD) and limit of quantitation (LOQ) were 2.12 ng mL(–1) and 7 ng mL(–1), respectively. The precisions of the method were ≤ 8.26%, and its accuracies were ≥ 95.32%. All the other validation parameters were satisfactory. The proposed method was successfully employed to the investigation of the pharmacokinetic profile of DUV in rats following a 25 mg/kg single dose of oral administration. CONCLUSION: The method is characterized with high sensitivity, accuracy, simple sample pretreatment, rapidity, eco-friendly as it consumes low volumes of organic solvent in the mobile phase and has high analysis throughput as its run time was short (~ 10 min).
format Online
Article
Text
id pubmed-8232391
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82323912021-06-28 A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats Sayed, Ahmed Y Khalil, Nasr Y Almomen, Aliyah Alzoman, Nourah Z Almehizia, Abdulrahman A Darwish, Ibrahim A Drug Des Devel Ther Original Research BACKGROUND: Duvelisib (DUV) is a new oral phosphoinositide-3-kinase (PI3K)-δ and PI3K-γ inhibitor. It has been recently granted an accelerated approval for treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is also effective in therapy of T-cell lymphoma, solid tumors, and non-Hodgkin’s lymphoma. In literature, there is no method valid for quantitation of DUV in human plasma for its therapeutic monitoring and pharmacokinetic studies. PURPOSE: The purpose of this study is the establishment of a highly sensitive HPLC method with fluorescence detection for quantitation of DUV in plasma for its therapeutic monitoring and pharmacokinetic studies of DUV. METHODS: The resolution of DUV and the internal standard (IS) olaparib (OLA) was achieved on Nucleosil CN column, with a mobile phase composed of acetonitrile:water (25:75, v/v) at a flow rate of 1.7 mL min(–1). The fluorescence of both DUV and OLA was detected at 410 nm after excitation at 280 nm. The method was validated according to the guidelines of bioanalytical method validation. RESULTS: The method was linear in the range of 5–100 ng mL(–1), and its limit of detection (LOD) and limit of quantitation (LOQ) were 2.12 ng mL(–1) and 7 ng mL(–1), respectively. The precisions of the method were ≤ 8.26%, and its accuracies were ≥ 95.32%. All the other validation parameters were satisfactory. The proposed method was successfully employed to the investigation of the pharmacokinetic profile of DUV in rats following a 25 mg/kg single dose of oral administration. CONCLUSION: The method is characterized with high sensitivity, accuracy, simple sample pretreatment, rapidity, eco-friendly as it consumes low volumes of organic solvent in the mobile phase and has high analysis throughput as its run time was short (~ 10 min). Dove 2021-06-21 /pmc/articles/PMC8232391/ /pubmed/34188446 http://dx.doi.org/10.2147/DDDT.S318714 Text en © 2021 Sayed et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sayed, Ahmed Y
Khalil, Nasr Y
Almomen, Aliyah
Alzoman, Nourah Z
Almehizia, Abdulrahman A
Darwish, Ibrahim A
A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats
title A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats
title_full A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats
title_fullStr A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats
title_full_unstemmed A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats
title_short A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats
title_sort highly sensitive nonextraction-assisted hplc method with fluorescence detection for quantification of duvelisib in plasma samples and its application to pharmacokinetic study in rats
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232391/
https://www.ncbi.nlm.nih.gov/pubmed/34188446
http://dx.doi.org/10.2147/DDDT.S318714
work_keys_str_mv AT sayedahmedy ahighlysensitivenonextractionassistedhplcmethodwithfluorescencedetectionforquantificationofduvelisibinplasmasamplesanditsapplicationtopharmacokineticstudyinrats
AT khalilnasry ahighlysensitivenonextractionassistedhplcmethodwithfluorescencedetectionforquantificationofduvelisibinplasmasamplesanditsapplicationtopharmacokineticstudyinrats
AT almomenaliyah ahighlysensitivenonextractionassistedhplcmethodwithfluorescencedetectionforquantificationofduvelisibinplasmasamplesanditsapplicationtopharmacokineticstudyinrats
AT alzomannourahz ahighlysensitivenonextractionassistedhplcmethodwithfluorescencedetectionforquantificationofduvelisibinplasmasamplesanditsapplicationtopharmacokineticstudyinrats
AT almehiziaabdulrahmana ahighlysensitivenonextractionassistedhplcmethodwithfluorescencedetectionforquantificationofduvelisibinplasmasamplesanditsapplicationtopharmacokineticstudyinrats
AT darwishibrahima ahighlysensitivenonextractionassistedhplcmethodwithfluorescencedetectionforquantificationofduvelisibinplasmasamplesanditsapplicationtopharmacokineticstudyinrats
AT sayedahmedy highlysensitivenonextractionassistedhplcmethodwithfluorescencedetectionforquantificationofduvelisibinplasmasamplesanditsapplicationtopharmacokineticstudyinrats
AT khalilnasry highlysensitivenonextractionassistedhplcmethodwithfluorescencedetectionforquantificationofduvelisibinplasmasamplesanditsapplicationtopharmacokineticstudyinrats
AT almomenaliyah highlysensitivenonextractionassistedhplcmethodwithfluorescencedetectionforquantificationofduvelisibinplasmasamplesanditsapplicationtopharmacokineticstudyinrats
AT alzomannourahz highlysensitivenonextractionassistedhplcmethodwithfluorescencedetectionforquantificationofduvelisibinplasmasamplesanditsapplicationtopharmacokineticstudyinrats
AT almehiziaabdulrahmana highlysensitivenonextractionassistedhplcmethodwithfluorescencedetectionforquantificationofduvelisibinplasmasamplesanditsapplicationtopharmacokineticstudyinrats
AT darwishibrahima highlysensitivenonextractionassistedhplcmethodwithfluorescencedetectionforquantificationofduvelisibinplasmasamplesanditsapplicationtopharmacokineticstudyinrats